The Lancet Microbe

The Lancet Microbe is a monthly gold open access journal published by Elsevier as part of The Lancet Group, launched in 2020 and dedicated to clinically relevant microbiology, with a 2025 Journal Impact Factor of 21.9《柳叶刀·微生物》是由爱思唯尔（Elsevier）作为（The Lancet Group）一部分出版的月刊金色开放获取期刊，2020 年创刊，聚焦临床相关微生物学，2025 年影响因子为 21.9。

Scope

• It publishes research on clinically relevant microbes at all scales, from antimicrobial resistance genes and virulence factors to the microbiome, and on to population level effects该刊刊载各尺度的临床相关微生物研究，从耐药基因与毒力因子，到微生物组，再到群体层面的效应。
• It covers pathogen biology, pathology including immunology, and population level effects such as outbreaks and epidemiology其涵盖病原体生物学、包括免疫学在内的病理学，以及暴发与流行病学等群体层面效应。
• It includes early phase clinical trials and other interventional studies when the outcomes are focused on the pathogen该刊收录以病原体为主要结局指标的早期临床试验及其他干预性研究。
• It aims to be a destination for the best microbiology-focused clinical research, handled with the rigour expected of any journal in the Lancet family该刊致力于成为最佳微生物学导向临床研究的发表平台，并以（Lancet）家族刊物一贯的严谨标准处理稿件。
• It also advocates for and collaborates with the microbial research community该刊还倡导并与微生物研究界开展协作。
• As a gold open access title, every article is free to read online with no subscription charge作为金色开放获取期刊，全部文章均可在线免费阅读，无需订阅。

History

• It was launched in 2020 as a new gold open access title within The Lancet Group该刊于 2020 年作为（The Lancet Group）内的新金色开放获取子刊创刊。
• Its first issue appeared in May 2020, opening with an editorial titled "Start as we mean to go on"其创刊号于 2020 年 5 月出版，卷首社论阐明了办刊宗旨。^[1]
• It belongs to the Lancet gold open access programme, alongside The Lancet Global Health, The Lancet Public Health and The Lancet Digital Health该刊与（The Lancet Global Health）（The Lancet Public Health）（The Lancet Digital Health）等同属（Lancet）金色开放获取计划。
• It posted a first Journal Impact Factor of 86.2 in the 2022 Journal Citation Reports该刊在 2022 年期刊引证报告中获得首个影响因子 86.2。
• Its impact factor moved from 86.208 in 2022 and 20.4 in 2024 to 21.9 in 2025其影响因子由 2022 年的 86.208、2024 年的 20.4 变化到 2025 年的 21.9。
• In the 2025 Journal Citation Reports it ranks second among 141 journals in infectious diseases and fourth among 167 in microbiology在 2025 年期刊引证报告中，该刊在传染病类别的 141 种期刊中位列第二，在微生物学类别的 167 种期刊中位列第四。

Editors

• Its Editor-in-Chief is Onisillos Sekkides, who has led the journal since 2019现任主编为 Onisillos Sekkides，自 2019 年起领导该刊。
• He works from The Lancet's London office, where the journal's in-house editorial team is based他在（The Lancet）伦敦办公室工作，该刊内部编辑团队亦设于此。
• Original research is peer reviewed externally for clinical and statistical quality, in keeping with the Lancet family model原创研究须经外部临床与统计质量同行评审，沿用（Lancet）家族模式。
• Submissions are first assessed by the in-house editorial team before being sent for external review来稿先由内部编辑团队初筛，再送外部评审。
• An International Advisory Board of researchers from many countries supports the journal's editorial direction该刊设有由多国研究者组成的国际顾问委员会，为编辑方向提供支持。